Fruit Flies: From Model Organism to Medical Marvel in Pharmaceutical Research

Fruit fly, or Drosophila melanogaster, is becoming a cornerstone model organism for biomedical research as a result of its genetic tractability, affordability, and high conservation of genetic pathways with humans. Drosophila has developed from a classical genetics model to a robust system for research into human diseases and drug discovery. The small body size, brief life cycle, and high reproductive rates of the fruit fly render it a suitable organism for big-scale, high-throughput researches. Around 75% of disease-causing genes in humans have functional homologues in drosophila, enabling scientists to explore a broad range of diseases such as neurodegenerative disorders, cancers, epilepsy, metabolic syndromes, cardiovascular diseases, and infectious diseases. It’s completely sequenced genome, along with sophisticated genetic manipulative tools like CRISPR, RNAi, and transgenic technologies, enables specific gene manipulation. Behavioral and physiological tests from memory assays to seizure susceptibility allow functional in vivo studies. Drug discovery applications are broad, with routes of administration from feeding to inhalation and injection. Fly models have been employed in assessing drug efficacy, screening new compounds, and delineating pharmacogenetic heterogeneity. Technological innovations now allow seamless integration with human genotype-phenotype databases, making drosophila more useful in translational research. In addition, the model has helped in the discovery of novel targets for treatments and evaluating toxicity and environment impact. Drosophila melanogaster remains a vital tool in deciphering disease mechanisms and the design of new therapeutic intervention. This review provides the overview and applications of fruit flies in various diseases.